Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion
Abstract
Echinomycin was administered to 43 patients with advanced cancer in escalating doses ranging from 60 to 2128 mcg/m2. The dose-limiting toxicity of echinomycin administered as a 24-h continuous infusion every 28 days was nausea and vomiting beginning at the end of the 24 h infusion and lasting from 3 to 8 days. Other toxicities included sporadic thrombocytopenia and biochemical evidence of liver dysfunction characterized by elevations in SGOT. Peripheral vein phlebitis was noted in 100% of patients, and watery diarrhea of 24-48-h duration was noted in 7% of patients. The maximally tolerated dose of echinomycin was 2128 mcg/m2. The recommended dose for phase II trials utilizing the 24-h continuous infusion schedule is 1600 mcg/m2 repeated every 28 days with pretreatment antiemetics.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CrEL-echinomycin caused severe nausea and vomiting, constituting its dose-limiting toxicity.
“CrEL-echinomycin also caused severe nausea and vomiting, constituting its dose-limiting toxicity11, 12, 15-21.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [20]
Cites
Structure revision of the antibiotic echinomycin
Dell, A., Williams, D. H., Morris, H. R., Smith, G. A., Feeney, J., & Roberts, G. C. K. (1975) · Journal of the American Chemical Society · doi:10.1021/ja00842a029 · Cited by 319 · see citing works
Echinomycin Binding Sites on DNA
Van Dyke, M. M., & Dervan, P. B. (1984) · Science · doi:10.1126/science.6089341 · Cited by 218 · see citing works
The binding of echinomycin to deoxyribonucleic acid
Wakelin, L. P. G., & Waring, M. J. (1976) · Biochemical Journal · doi:10.1042/bj1570721 · Cited by 161 · see citing works
Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
Grem, J. L., Tutsch, K. D., Simon, K., et al. (1987) · PubMed · Cited by 102 · see citing works
Stoffwechselprodukte von Actinomyceten. 7. Mitteilung. Echinomycin
Corbaz, R., Ettlinger, L., Gäumann, E., KELLER‐SCHIERLEIN, W., Kradolfer, F., Neipp, L., Prelog, V., Reusser, P., & Zähner, H. (1957) · Helvetica Chimica Acta · doi:10.1002/hlca.19570400124 · Cited by 96 · see citing works
Echinomycin: The first bifunctional intercalating agent in clinical trials
Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B. (1985) · Investigational New Drugs · doi:10.1007/bf00170766 · Cited by 61 · see citing works
Structure of quinomycin antibiotics.
Martin, D. G., MIZSAK, S. A., Biles, C., STEWART, J. C., Baczynskyj, L., & Meulman, P. A. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.332 · Cited by 56 · see citing works
Clinical trials in cancer chemotherapy
Carter, S. K. (1977) · Cancer · doi:10.1002/1097-0142(197707)40:1+ · Cited by 49 · see citing works
Studies on quinoxaline antibiotics. II. Isolation and properties of quinomycins A, B and C.
Yoshida, T., KATAGIRI, K., & YOKOZAWA, S. (1961) · PubMed · Cited by 33 · see citing works
Phase I study of echinomycin administered on an intermittent bolus schedule.
Jh, H., McFadden, M., Andrews, W. G., Pj, B., Ahlgren, J. D., & Pv, W. (1985) · PubMed · Cited by 16 · see citing works
Cytotoxic Activity of Echinomycin in a Human Tumor Cloning System
Lathan, B., & Hoff, D. D. V. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.191 · Cited by 14 · see citing works
STUDIES ON QUINOXALINE ANTIBIOTICS. IV. SELECTIVE ANTITUMOR ACTIVITY OF EACH QUINOXALINE ANTIBIOTIC.
MATSUURA, S. (1965) · PubMed · Cited by 14 · see citing works
(1987) · PubMed · Cited by 11 · see citing works
Cobb, W. R., Bogdén, A. E., Reich, S. D., Griffin, T. W., Kelton, D., & LePage, D. (1983) · Investigational New Drugs · doi:10.1007/bf00180186 · Cited by 10 · see citing works
Inhibition of RNA synthesis in E. coli protoplasts by quinomycins A and C.
Sato, K., Yoshida, T., & Katagiri, K. (1967) · PubMed · Cited by 8 · see citing works
Tsunoda, A. (1962) · PubMed · Cited by 6 · see citing works
Chemoprophylaxis of poliomyelitis in mice with quinomycin.
Tsunoda, A. (1962) · Journal of antibiotics, series A/The journal of antibiotics. Series A · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wang, Y., Liu, Y., Tang, F., Bernot, K. M., Schore, R., Marcucci, G., Caligiuri, M. A., Zheng, P., & Liu, Y. (2014) · Blood · doi:10.1182/blood-2013-12-544221 · Cited by 69 · see citing works
Gradishar, W. J., Vogelzang, N. J., Kilton, L. J., Leibach, S. J., Rademaker, A. W., French, S., & Benson, A. B. (1995) · Investigational New Drugs · doi:10.1007/bf00872868 · Cited by 49 · see citing works
Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · see citing works
Schilsky, R. L., Faraggi, D., Korzun, A., Vogelzang, N., Ellerton, J., Wood, W., & Henderson, I. C. (1991) · Investigational New Drugs · doi:10.1007/bf00176982 · Cited by 21 · see citing works
- Authors
- Kuhn, J. G., Von Hoff, D. D., Hersh, M., Melink, T., Clark, G. M., Weiss, G. R., & Coltman, C. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Kuhn, John G.
- Venue
- European Journal of Cancer and Clinical Oncology
- Publisher
- Elsevier BV
- Published
- 1989-05
- Volume
- 25
- Issue
- 5
- Pages
- 797-803
- ISSN
- 0277-5379 (ISSN-L)
- OpenAlex
- W2008931212
- Cited by
- 14
- References
- 17
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2017: 1 · 2015: 1 · 2014: 1
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Cancer and Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01cm027542-005)
- National Cancer Institute (N-01-CM-27542)
- National Center for Research Resources (RR-01346)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- echinomycin, continuous infusion chemotherapy, advanced cancer, dose-limiting toxicity, nausea and vomiting, thrombocytopenia, liver dysfunction, diarrhea, maximum tolerated dose
- MeSH terms
- Adult, Aged, Drug Evaluation, Echinomycin, Female, Humans, Infusions, Intravenous, Liver Function Tests, Male, Middle Aged, Nausea, Neoplasms, Platelet Count, Quinoxalines, Thrombocytopenia, Vomiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
